



HAL
open science

Analyse phénotypique et génotypique de 30 patients ayant une épidermolyse bulleuse héréditaire de type jonctionnelle avec mutations du gène codant pour le collagène XVII, COL17A1

Anne-Laure Hérissé

► **To cite this version:**

Anne-Laure Hérissé. Analyse phénotypique et génotypique de 30 patients ayant une épidermolyse bulleuse héréditaire de type jonctionnelle avec mutations du gène codant pour le collagène XVII, COL17A1. Médecine humaine et pathologie. 2015. dumas-01362337

HAL Id: dumas-01362337

<https://dumas.ccsd.cnrs.fr/dumas-01362337>

Submitted on 8 Sep 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

UNIVERSITE DE NICE SOPHIA ANTIPOLIS
FACULTE DE MEDECINE DE NICE

ANALYSE PHENOTYPIQUE ET GENOTYPIQUE DE 30 PATIENTS
AYANT UNE EPIDERMOLYSE BULLEUSE HEREDITAIRE
DE TYPE JONCTIONNELLE
AVEC MUTATIONS DU GENE CODANT POUR LE COLLAGENE XVII,
COL17A1.

THESE D'EXERCICE EN MEDECINE

Par

Anne-Laure Hérissé

Présentée et soutenue publiquement le 6 octobre 2015

COMPOSITION DU JURY :

Président du jury : Monsieur le Professeur Jean-Philippe LACOUR

Directrice de Thèse : Madame le Docteur Christine CHIAVERINI

Assesseurs : Monsieur le Professeur Etienne BERARD

Monsieur le Professeur Pierre MARTY

Monsieur le Docteur Hervé HAAS



UNIVERSITÉ NICE-SOPHIA ANTIPOLIS

FACULTÉ DE MÉDECINE

Liste des professeurs au **1er septembre 2015** à la Faculté de Médecine de Nice

Doyen	M. BAQUÉ Patrick
Vice-Doyen	M. BOILEAU Pascal
Assesseurs	M. ESNAULT Vincent M. CARLES Michel Mme BREUIL Véronique M. MARTY Pierre
Conservateur de la bibliothèque	Mme DE LEMOS Annelise
Directrice administrative des services	Mme CALLEA Isabelle
Doyens Honoraires	M. AYRAUD Noël M. RAMPAL Patrick M. BENCHIMOL Daniel
Professeurs Honoraires	
M. BALAS Daniel	M. LALANNE Claude-Michel
M. BATT Michel	M. LAMBERT Jean-Claude
M. BLAIVE Bruno	M. LAZDUNSKI Michel
M. BOQUET Patrice	M. LEFEBVRE Jean-Claude
M. BOURGEON André	M. LE BAS Pierre
M. BOUTTÉ Patrick	M. LE FICHOUX Yves
M. BRUNETON Jean-Noël	Mme LEBRETON Elisabeth
Mme BUSSIERE Françoise	M. LOUBIERE Robert
M. CAMOUS Jean-Pierre	M. MARIANI Roger
M. CHATEL Marcel	M. MASSEYEFF René
M. COUSSEMENT Alain	M. MATTEI Mathieu
M. DARCOURT Guy	M. MOUIEL Jean
M. DELLAMONICA Pierre	Mme MYQUEL Martine
M. DELMONT Jean	M. OLLIER Amédée
M. DEMARD François	M. ORTONNE Jean-Paul
M. DOLISI Claude	M. SAUTRON Jean Baptiste
M. FRANCO Alain	M. SCHNEIDER Maurice
M. FREYCHET Pierre	M. SERRES Jean-Jacques
M. GÉRARD Jean-Pierre	M. TOUBOL Jacques
M. GILLET Jean-Yves	M. TRAN Dinh Khiem
M. GRELLIER Patrick	M VAN OBBERGHEN Emmanuel
M. HARTER Michel	M. ZIEGLER Gérard
M. INGLESAKIS Jean-André	

M.C.A. Honoraire

Mlle ALLINE Madeleine

M.C.U. Honoraires

M. ARNOLD Jacques
 M. BASTERIS Bernard
 Mlle CHICHMANIAN Rose-Marie
 Mme DONZEAU Michèle
 M. EMILIOZZI Roméo
 M. FRANKEN Philippe
 M. GASTAUD Marcel
 M. GIRARD-PIPAU Fernand
 M. GIUDICELLI Jean
 M. MAGNÉ Jacques
 Mme MEMRAN Nadine
 M. MENGUAL Raymond
 M. POIRÉE Jean-Claude
 Mme ROURE Marie-Claire

PROFESSEURS CLASSE EXCEPTIONNELLE

M.	AMIEL Jean	Urologie (52.04)
M.	BENCHIMOL Daniel	Chirurgie Générale (53.02)
M.	BOILEAU Pascal	Chirurgie Orthopédique et Traumatologique (50.02)
M.	DARCOURT Jacques	Biophysique et Médecine Nucléaire (43.01)
M.	DESNUELLE Claude	Biologie Cellulaire (44.03)
Mme	EULLER-ZIEGLER Liana	Rhumatologie (50.01)
M.	FENICHEL Patrick	Biologie du Développement et de la Reproduction (54.05)
M.	FUZIBET Jean-Gabriel	Médecine Interne (53.01)
M.	GASTAUD Pierre	Ophtalmologie (55.02)
M.	GILSON Éric	Biologie Cellulaire (44.03)
M.	GRIMAUD Dominique	Anesthésiologie et Réanimation Chirurgicale (48.01)
M.	HASSEN KHODJA Reda	Chirurgie Vasculaire (51.04)
M.	HÉBUTERNE Xavier	Nutrition (44.04)
M.	HOFMAN Paul	Anatomie et Cytologie Pathologiques (42.03)
M.	LACOUR Jean-Philippe	Dermato-Vénérologie (50.03)
M.	MARTY Pierre	Parasitologie et Mycologie (45.02)
M.	MICHIELS Jean-François	Anatomie et Cytologie Pathologiques (42.03)
M.	MOUROUX Jérôme	Chirurgie Thoracique et Cardiovasculaire (51.03)
M.	PAQUIS Philippe	Neurochirurgie (49.02)
M.	PRINGUEY Dominique	Psychiatrie d'Adultes (49.03)
M.	QUATREHOMME Gérald	Médecine Légale et Droit de la Santé (46.03)
M.	M.ROBERT Philippe	Psychiatrie d'Adultes (49.03)
M.	SANTINI Joseph	O.R.L. (55.01)
M.	THYSS Antoine	Cancérologie, Radiothérapie (47.02)

PROFESSEURS PREMIERE CLASSE

Mme	ASKENAZY-GITTARD Florence	Pédopsychiatrie (49.04)
M.	BAQUÉ Patrick	Anatomie - Chirurgie Générale (42.01)
M.	BÉRARD Étienne	Pédiatrie (54.01)
M.	BERNARDIN Gilles	Réanimation Médicale (48.02)
M.	BONGAIN André	Gynécologie-Obstétrique (54.03)
M.	CASTILLO Laurent	O.R.L. (55.01)
Mme	CRENESSE Dominique	Physiologie (44.02)
M.	DE PERETTI Fernand	Anatomie-Chirurgie Orthopédique (42.01)
M.	DRICI Milou-Daniel	Pharmacologie Clinique (48.03)
M.	ESNAULT Vincent	Néphrologie (52-03)
M.	FERRARI Émile	Cardiologie (51.02)
M.	FERRERO Jean-Marc	Cancérologie ; Radiothérapie (47.02)
M.	GIBELIN Pierre	Cardiologie (51.02)
M.	GUGENHEIM Jean	Chirurgie Digestive (52.02)
Mme	ICHAÏ Carole	Anesthésiologie et Réanimation Chirurgicale (48.01)
M.	LONJON Michel	Neurochirurgie (49.02)
M.	MARQUETTE Charles-Hugo	Pneumologie (51.01)
M.	MOUNIER Nicolas	Cancérologie, Radiothérapie (47.02)
M.	PADOVANI Bernard	Radiologie et Imagerie Médicale (43.02)
Mme	PAQUIS Véronique	Génétique (47.04)
M.	PRADIER Christian	Épidémiologie, Économie de la Santé et Prévention (46.01)
M.	RAUCOULES-AIMÉ Marc	Anesthésie et Réanimation Chirurgicale (48.01)
Mme	RAYNAUD Dominique	Hématologie (47.01)
M.	ROSENTHAL Éric	Médecine Interne (53.01)
M.	SCHNEIDER Stéphane	Nutrition (44.04)
M.	STACCINI Pascal	Biostatistiques et Informatique Médicale (46.04)
M.	THOMAS Pierre	Neurologie (49.01)
M.	TRAN Albert	Hépto Gastro-entérologie (52.01)

PROFESSEURS DEUXIEME CLASSE

M.	ALBERTINI Marc	Pédiatrie (54.01)
Mme	BAILLIF Stéphanie	Ophthalmologie (55.02)
M.	BAHADORAN Philippe	Cytologie et Histologie (42.02)
M.	BARRANGER Emmanuel	Gynécologie Obstétrique (54.03)
M.	BENIZRI Emmanuel	Chirurgie Générale (53.02)
M.	BENOIT Michel	Psychiatrie (49.03)
Mme	BLANC-PEDEUTOUR Florence	Cancérologie – Génétique (47.02)
M.	BREAUD Jean	Chirurgie Infantile (54-02)
Mlle	BREUIL Véronique	Rhumatologie (50.01)
M.	CANIVET Bertrand	Médecine Interne (53.01)
M.	CARLES Michel	Anesthésiologie Réanimation (48.01)
M.	CASSUTO Jill-Patrice	Hématologie et Transfusion (47.01)
M.	CHEVALLIER Patrick	Radiologie et Imagerie Médicale (43.02)
Mme	CHINETTI Giulia	Biochimie-Biologie Moléculaire (44.01)
M.	DELOTTE Jérôme	Gynécologie-obstétrique (54.03)
M.	DUMONTIER Christian	Chirurgie plastique
M.	FONTAINE Denys	Neurochirurgie (49.02)
M.	FOURNIER Jean-Paul	Thérapeutique (48-04)
M.	FREDENRICH Alexandre	Endocrinologie, Diabète et Maladies métaboliques (54.04)
Mlle	GIORDANENGO Valérie	Bactériologie-Virologie (45.01)
M.	GUÉRIN Olivier	Gériatrie (48.04)
M.	HANNOUN-LEVI Jean-Michel	Cancérologie ; Radiothérapie (47.02)

PROFESSEURS DEUXIEME CLASSE (suite)

M.	IANNELLI Antonio	Chirurgie Digestive (52.02)
M	JEAN BAPTISTE Elixène	Chirurgie vasculaire (51.04)
M.	JOURDAN Jacques	Chirurgie Thoracique et Cardiovasculaire (51.03)
M.	LEVRAUT Jacques	Anesthésiologie et Réanimation Chirurgicale (48.01)
M.	PASSERON Thierry	Dermato-Vénéréologie (50.03)
M.	PICHE Thierry	Gastro-entérologie (52.01)
M.	ROGER Pierre-Marie	Maladies Infectieuses ; Maladies Tropicales (45.03)
M.	ROHRLICH Pierre	Pédiatrie (54.01)
M.	RUIMY Raymond	Bactériologie-virologie (45.01)
Mme	SACCONI Sabrina	Neurologie (49.01)
M.	SADOUL Jean-Louis	Endocrinologie, Diabète et Maladies Métaboliques (54.04)
M.	TROJANI Christophe	Chirurgie Orthopédique et Traumatologique (50.02)
M.	VENISSAC Nicolas	Chirurgie Thoracique et Cardiovasculaire (51.03)

PROFESSEUR DES UNIVERSITÉS

M.	HOFLIGER Philippe	Médecine Générale
----	-------------------	-------------------

PROFESSEUR AGRÉGÉ

Mme	LANDI Rebecca	Anglais
Mme	ROSE	Anglais

MAITRES DE CONFÉRENCES DES UNIVERSITÉS - PRATICIENS HOSPITALIERS

Mme	ALUNNI Véronique	Médecine Légale et Droit de la Santé (46.03)
M.	AMBROSETTI Damien	Cytologie et Histologie (42.02)
Mme	BANNWARTH Sylvie	Génétique (47.04)
M.	BENOLIEL José	Biophysique et Médecine Nucléaire (43.01)
Mme	BERNARD-POMIER Ghislaine	Immunologie (47.03)
Mme	BUREL-VANDENBOS Fanny	Anatomie et Cytologie pathologiques (42.03)
M.	DOGLIO Alain	Bactériologie-Virologie (45.01)
M	DOYEN Jérôme	Radiothérapie (47.02)
M	FAVRE Guillaume	Néphrologie (52.03)
M.	FOSSE Thierry	Bactériologie-Virologie-Hygiène (45.01)
M.	GARRAFFO Rodolphe	Pharmacologie Fondamentale (48.03)
Mme	GIOVANNINI-CHAMI Lisa	Pédiatrie (54.01)
Mme	HINAULT Charlotte	Biochimie et biologie moléculaire (44.01)
Mme	LEGROS Laurence	Hématologie et Transfusion (47.01)
Mme	MAGNIÉ Marie-Noëlle	Physiologie (44.02)
Mme	MOCERI Pamela	Cardiologie (51.02)
Mme	MUSSO-LASSALLE Sandra	Anatomie et Cytologie pathologiques (42.03)
M.	NAÏMI Mourad	Biochimie et Biologie moléculaire (44.01)
M.	PHILIP Patrick	Cytologie et Histologie (42.02)
Mme	POMARES Christelle	Parasitologie et mycologie (45.02)
M.	ROUX Christian	Rhumatologie (50.01)
M.	TESTA Jean	Épidémiologie Économie de la Santé et Prévention (46.01)
M.	TOULON Pierre	Hématologie et Transfusion (47.01)

PROFESSEURS ASSOCIÉS

M	BALDIN Jean-Luc	Médecine Générale
M	COYNE John	Anatomie et Cytologie (42.03)
M.	GARDON Gilles	Médecine Générale
Mme	PACZESNY Sophie	Hématologie (47.01)

MAITRES DE CONFÉRENCES ASSOCIÉS

M.	DARMON David	Médecine Générale
Mme	MONNIER Brigitte	Médecine Générale

PROFESSEURS CONVENTIONNÉS DE L'UNIVERSITÉ

M.	BERTRAND François	Médecine Interne
M.	BROCKER Patrice	Médecine Interne Option Gériatrie
M.	CHEVALLIER Daniel	Urologie
Mme	FOURNIER-MEHOUAS Manuella	Médecine Physique et Réadaptation
M.	JAMBOU Patrick	Coordination prélèvements d'organes
M.	QUARANTA Jean-François	Santé Publique

REMERCIEMENTS

Au Docteur Christine Chiaverini, MERCI de m'avoir fait l'honneur de diriger cette thèse et de m'avoir accordé ta confiance. Ton professionnalisme, ta rigueur et ton humanité sont pour moi un exemple,

A Monsieur le Professeur Lacour, pour me faire l'honneur de présider mon jury. Je vous remercie pour votre confiance et votre disponibilité. Votre passion pour la Dermatologie et son enseignement est un exemple pour tous,

Au Professeur Bérard, au Professeur Marty, au Docteur Haas, pour avoir porté intérêt au sujet de ma thèse et avoir accepté de juger mon travail. Je vous remercie pour votre soutien et votre confiance,

A tous les médecins ayant participé à ce travail,

A ma famille,

A mes parents et Alex, Merci pour votre soutien, pour m'avoir permis de devenir celle que je suis aujourd'hui !

A Jacqueline, merci pour ton soutien sans faille, ces 5 ans passés près de toi m'ont permis de découvrir la femme fantastique que tu es,

A Sylvain, ta présence et ton soutien à chaque instant de la vie font de moi la femme la plus heureuse ! Je t'aime !

A mes amis,

A mes amis d'enfance, Solenne, Tony, Aude, Kévin, Anne-Sophie, JP, Sandrine, Fred : Merci d'être là !! Vous êtes fantastique ! Je vous aime !

A Florence, Benjamin, Sarah, Marjo, Leila, Angéline, Frédéric, Rania, Céline, Sébastien (le tien), Anne, Isabelle, Sébastien, Myriam : Merci pour tous les bons moments passés à vos côtés ! Je vous aime !

A mes co-internes de pédiatrie : vous êtes génial(e)s ! Restez comme vous êtes !

Aux belles amitiés nées tout au long de mon parcours médical :

A l'équipe des urgences pédiatriques : Vous êtes top ! C'est un vrai bonheur de travailler chaque jour avec vous !

A l'équipe du laboratoire de Parasitologie : Je vous remercie pour votre encadrement et votre soutien pendant mon master !

A l'équipe de Dermatologie : Merci pour votre accueil et votre soutien !

A l'équipe de Réanimation néonatale, à l'équipe de radiologie pédiatrique : Merci pour votre accueil, votre enseignement et votre soutien !

A toutes les personnes ayant croisé mon chemin pendant mes études que j'aurai oubliées de citer.

Un grand MERCI à tous !!

TABLES DES MATIERES

Abréviations	9
INTRODUCTION	10
MATERIEL & METHODES	11
1- Patients	11
2- Immunofluorescence	11
3- Analyses moléculaires du gène <i>COL17A1</i>	12
RESULTATS	13
1- Patients	13
2- Caractéristiques cliniques	
A. Fréquence élevée des aplasies cutanées congénitales	14
B. Evolution de l'atteinte dermatologique au cours du temps	15
3- Résultats de l'immunofluorescence	16
4- Résultats du séquençage du gène <i>COL17A1</i>	17
5- Corrélations phénotypiques-génotypiques	18
DISCUSSION	20
REFERENCES	23
ANNEXES	25
1- Figure 1: Phenotypic variability in Junctional Epidermolysis Bullosa patients with <i>COL17A1</i> mutations.	
2- Figure 2: Distribution of collagen XVII mutations in this study. Schematic representation of the protein with corresponding domains and binding site proteins.	
3- Table 1: Summary of clinical, immunohistological and molecular data of patients.	
SERMENT D'HIPPOCRATE	28

ABBREVIATIONS

EB : Epidermolysis Bullosa

JEB : Junctional Epidermolysis Bullosa

DEB : Dystrophic Epidermolysis Bullosa

COL17A1 : Genetic name of Collagen XVII

PCR : Polymerase Chain Reaction

DNA : Deoxyribonucleic acid

RNA : Ribonucleic acid

BMZ : Basement membrane zone

HD : Hemidesmosome

CCA : Congenital cutis aplasia

NC domain : Non Collagenous domain

X : PTC - Premature Termination Codon

SS : Splice site mutation

A : Ala - Alanine (amino acid)

E : Glu - Acide glutamique (amino acid)

G : Gly - Glycine (amino acid)

Y : Tyr - Tyrosine (amino acid)

L : Leu - Leucine (amino acid)

Q : Gln - Glutamine (amino acid)

R : Arg - Arginine (amino acid)

S : Ser - Serine (amino acid)

NA : Non Available

PMD : Psycho motor delay

Ins : Insertion mutation

Del : Deletion mutation

INTRODUCTION

Inherited epidermolysis bullosa (EB) is a heterogeneous group of rare recessively inherited genodermatoses characterized by skin and/or mucosal fragility resulting in blistering. International consensus meetings on diagnosis and classification of EB have categorized four major EB types: simplex EB, junctional EB, dystrophic EB and Kindler syndrome based on the level of cleavage of the blister within the skin [1, 2 and 3]. Consistent with this classification, junctional epidermolysis bullosa (JEB) includes all subtypes of EB in which blisters develop within the dermal-epidermal junction of the integument, at the level of the lamina lucida of the basement membrane zone. JEB, which comprises a variety of generalized and localized subtypes, is associated with genetic mutations affecting one of the of six candidate genes expressing the components of the hemidesmosome-anchoring filament adhesion complex [2, 3, 4 and 7]. Collagen XVII, a hemidesmosome transmembrane component, consists of an N-terminal intracytoplasmic domain that binds to integrin $\beta 4$ and to the inner hemidesmosome plaque components plectin and BP230, a short transmembrane domain and a C-terminal extracellular domain with 15 collagenic domains and 16 non-collagenic domains. This ectodomain contains the binding sites for laminin 332, integrin $\alpha 6$ and collagen IV [4, 5, 6, 7 and 8]. Genetic mutations in the *COL17A1* gene that encodes collagen XVII result in either localized or generalized intermediate JEB. Recently, *COL17A1* mutations have been involved in autosomal dominant diseases, such as a dominantly-inherited epithelial recurrent erosion dystrophy (ERED)-like disease common in northern Sweden [9] and a novel form of random pitting, dental enamel hypoplasia described in USA [10]. Less than 100 JEB patients with clinical phenotype and molecular analysis have so far been reported in the literature [2, 3].

The aim of our study was to contribute to the establishment of genotype-phenotype profiles in patients with JEB associated with *COL17A1* genetic mutations.

MATERIAL AND METHODS

1- Patients:

All patients were diagnosed as JEB with collagen XVII alterations by immunofluorescence analysis of skin biopsies and/or molecular analysis of *COL17A1* genetic mutations in our center between June 1993 and July 2015. When available, medical and biological records were collected with the help of a standardized questionnaire (age at diagnosis, extent of skin lesion, mucosal involvement, cutaneous infections, skin cancers, nail dystrophy, alopecia, digestive problems and malnutrition, orthopedic abnormalities, geographical origin and social insertion).

2- Immunofluorescence analysis:

The level of blister formation and protein expression were determined using frozen skin biopsies. Monoclonal antibodies were HD121 to plectin (gift of Dr Owaribe, Japan), GoH3 to integrin $\alpha 6$ (kind gift of A. Sonnenberg, Amsterdam, Netherlands); 3E1 (Gibco BRL Life Technologies, Cergy Pontoise, France) to integrin $\beta 4$; 233 (kind gift of Dr Owaribe, Japan) specific to the collagen type XVII; GB3 to laminin-5 (our production), LH7:2 (Cymbus Biotechnology, Chandlers Ford, UK) to collagen type VII. Secondary antibodies were fluorescein isothiocyanate conjugated goat antimouse Ig (Dako, Trappes, France), goat antirat IgG (Cappel, ICN Biomedicals, Orsay, France), or swine antirabbit Ig (Dako, Ville, France) [11]. The tissue sections were examined using an epiluminescence Zeiss Axiophot microscope.

3- Molecular analysis of COL17A1 gene:

Genomic DNA was isolated from peripheral blood of the patients, their parents when available and unrelated controls using the QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). All exons of the *COL17A1* gene were amplified by Polymerase Chain Reaction (PCR) using 50-100 ng of genomic DNA as template in 25- μ l reactions with 20pmol each of flanking intronic primers and 0.5 U Taq-Polymerase (Life Technologies, St. Aubin, France). The PCR products were purified using QIAGEN PCR Purification Kit (Qiagen, Hilden Germany), then subjected to cycle sequencing with Big Dye Terminator Cycle Sequencing Kit (according to manufacturer's recommendations, ABI-Life Technologies, Carlsbad, CA USA) and analyzed on an ABI PRISM 310 Genetic Analyser (ABI-Life Technologies, Carlsbad, CA USA). The designation of mutations and numbering of the nucleotides and amino acids was performed according to nomenclature recommendations.

RESULTS

1- Patients:

Thirty patients were included, sex ratio = 1, middle age 13 years old (from 0 to 74 years) (Table 1) divided into: eleven adults over 18, seven teenagers (from 13 to 17 y-o), four children (from 3 to 12 y-o) and eight infants (from 0 to 2 y-o). Fifteen of them were products of non-consanguineous unions. Sixteen patients were from France, six from Maghreb, three from Italy, and one each from Spain, Cape Verde, Mali, Turkey and Arabic Emirates. Patients 22 and 23 were brothers. Diagnosis was established at birth for 16/30 patients, during childhood for 6/30 patients, in adolescence for 1/30 patients, in adulthood for 7/30 patients. Twenty-two patients presented a generalized form, one a late onset of the condition, the mutation of which has previously been published [12] and two a localized form. No clinical data were available for five patients. The first symptoms appeared in the neonatal period for 19/25 patients, between the first month of life and 2 y-o for 5/25 patients, in childhood for one patient. Three patients died during their first year of life. Detailed clinical data were available only for 25 patients.

2- Clinical features (Table 1 and Fig 1):

A. High frequency of extensive congenital cutis aplasia:

Fourteen of 25 patients presented with congenital cutis aplasia (CCA). Among these 14 patients, CCA localized on the four limbs (hands, feet and/or legs) in 10 cases, on the lower limbs in 2 patients and once on the hands. Hospitalization in neonatology department was required for all patients for dressings and analgesic treatments. CCA was associated with the most severe forms of generalized intermediate JEB with important skin fragility and nail dystrophy. Three patients presenting CCA died in their first months of life. No functional sequelae were reported after complete healing of CCA, except for patient 9 who presented synechia of toes on his/her left foot.

B. Variable evolution of dermatological condition over time:

Phenotypic analysis showed a wide range of disease severity during infancy. In 16 patients the phenotype was severe, with exacerbated skin fragility, generalized blistering, CCA, severe mucosal involvement, nail and dental dystrophy, leading to demise in three cases. In 6 other patients, JEB was moderate with occasional blistering, mucosal involvement and inconstant dental and nail dystrophy. Finally, 3 patients were asymptomatic during infancy (Fig 1). Analysis of the disease course provided interesting information. Global evolution of the disease was favorable for 13 out of 25 patients, with progressive improvement of their skin condition, good social integration and personal development (marriage and children, employment, sport activity and autonomy for care). This was despite the fact that four of these patients suffered from a severe phenotype during infancy. In contrast to improvement of skin involvement, mucosal lesions persisted in adulthood in all patients, without noticeable improvement. In adulthood, uro-genital lesions, as anal fissures or urethral stricture, were the most common mucosal lesions observed, as well as crusted chronic lesions in the nose and buccal lesions. Evolution was unfavorable for 12 patients, including the three patients that died during their first months of life. Three adults suffered from malnutrition, social and personal difficulties. Six children had psycho-motor development and/or delayed growth, malnutrition, or extensive skin involvement with time-consuming dressings. Twenty-three among the 25 patients presented nail dystrophy, 15 had universal alopecia beginning in adolescence and 13 suffered from dental dystrophy, including enamel defects, caries and/or parodontitis. Chronic constipation was observed in 6 cases and renal failure in one (patient 5). No pyloric atresia, esophageal stricture or cancer was reported in our cohort.

3- Immunofluorescence analysis (table 1):

This was performed on skin biopsies obtained from 29 patients. It showed cleavage within the basal membrane zone, which is characteristic of JEB, with decreased fluorescent staining of collagen XVII at the roof and the floor of the blister in 4 patients (patients 15, 16, 24 and 25), negative staining in 25 patients, compared to healthy controls. In accordance with the diagnosis of JEB, collagen VII and laminin-5 were expressed and mapped to the blister floor; keratins and plectin to the blister roof and integrin $\alpha 6\beta 4$ both to the floor and roof of the blister.

4- Direct sequencing of genomic DNA (Table 1 and Fig 2):

Sequencing of genomic DNA identified 34 mutations in *COL17A1* gene in 28 patients, of which, to our knowledge, 24 are novel. No mutation was found after sequencing all exons of *COL17A1* gene for patient 25 and analysis is still ongoing for patient 9. Homozygous gene mutations were found in 19/28 patients and heterozygous mutations in 9/28 patients. Consanguineous couples were reported in 14 of 28 patients. Eleven of 34 mutations are nonsense mutations, 3 insertion and 9 deletion mutations predicted to lead to premature termination codon (PTC); 4 missense mutations and 6 splice site mutations. Splice site mutations concerned in 7 patients (patients 12, 20, 22, 23, 26, 28, and 29) for whom 3 mutations were novel. In patient 24, the change of c.3198c/t hampers the recognition of the natural 3' splice site of exon 46 which is 11 nucleotides downstream at c.3208. The exon-intron splice site is anticipated and occurs at c.3192 which results in the deletion of 16nt, and corresponds to p.Val1065_1070delLeufs.

Three mutations were found to be recurrent in our European patients. Mutation p.Arg1226X in exon 51 found in two unrelated patients from France and Spain (patients 6 and 19), mutation p.Gly446Ser in exon 17 found in two unrelated French patients (patients 20 and 21), and mutation p.Tyr207X in exon 10 found in two unrelated French patients (patients 11 and 15).

We observe that 19 of 34 mutations are localized in a collagenous domain of the protein, of which 8 mutations are in Col15 domain (Fig 2). Nine mutations are localized in binding site regions of which 8 are at the level of laminin-5 binding site and one at the level of plectin-BP230 binding site. Seventeen are localized in non-collagenous domain (NC) of which 2 are localized in NC16a ectodomain.

5- Phenotypic-genotypic correlations:

The wide spectrum of clinical phenotypes, the type and location of mutations in the *COL17A1* and the low rate of recurrent mutations explain the difficulties to define phenotype-genotype correlations. As expected, patients with glycine or arginine substitutions, in particular in the homozygous state, had milder phenotypes. Similarly, patient 16, homozygous for an in-frame 3-nucleotides insertion presented with a mild phenotype. Patients with splice site mutations also suffered from mild phenotypes, except for one patient (patient 12) who was a heterozygous composite with a nonsense mutation. As expected, patients with two nonsense mutations or mutations leading to premature stop codons usually were affected by the most severe phenotypes.

Patients 6 and 19 were compound heterozygotes for the recurrent mutation p.Arg1226X [17]. Patient 6, carrier of a PTC mutation in exon 26, died 3 months old; patient 19, carrier of a nonsense mutation in exon 52, presented a mild phenotype. Two unrelated French patients (patients 20 and 21) were compound heterozygotes for missense mutation p.Gly446Ser in exon 17, which resulted in mild phenotypes and favorable clinical course. Second mutations were a splice site mutation and a PTC mutation in exon 21 and 46, respectively. Both patients suffered from dental and nail involvement, mucosal involvement localized in buccal mucosa and uro-genital tract. The adult patient showed alopecia, which did not affect the adolescents; no CCA was observed in the neonatal period.

Two other unrelated French patients (patients 11 and 15) were homozygous for the PTC mutation p.Tyr207X in exon 10. This mutation localized in the intracellular domain of collagen XVII at level of the plectin-BP230 binding site. Patient 11, 54 years old with mild phenotype, suffered from dental abnormalities, alopecia and social difficulties, while in patient 15, 10 months old, the JEB phenotype was mild with limited skin involvement.

Three additional patients were homozygous for PTC mutations affecting the intracellular domain of collagen XVII. In patients 5 and 7, PTC mutations in exon 3 and 7, respectively, resulted in severe phenotypes, which was fatal for patient 5 who deceased in the first month of life while resulted in delayed psychomotor development and growth in patient 7. Interestingly, these severe manifestations

were linked to PTC localized upstream the binding domain for plectin-BP230, while PTC within in exon 17 located downstream the binding domain for plectin-BP230, just before the transmembrane domain, caused a moderate phenotype in Patient 17).

Eight mutations localized in the larger (col15) collagenic domain of collagen XVII. Patient 2 and 27 were homozygous for glycine substitutions, five patients (n° 3, 4, 6, 20 and 29) had PTC mutations, while patient 28 presented splice site mutations. Patients 2 and 3 showed very localized phenotypes, Patients 4 and 6 severe phenotypes, while patient 20 displayed a mild phenotype. No clinical data were available for patients 27, 28 and 29.

In five patients the genetic mutations affected one of the six exons encoding for the 6 C-terminal collagenic domains, where the binding sites for laminin-5 and collagen IV are predicted. Patient 1 had the already reported p.Arg1303Glu missense mutation leading to EBJ late onset. In the four other patients, the PTCs were either homozygous or compound heterozygous with distinct PTC mutations which resulted in various JEB phenotypes: Patient 6 presented with a lethal generalized intermediate JEB; in Patients 13 and 14 JEB was generalized with malnutrition, and moderate in patient 19 with a favorable clinical course.

Finally, patient 24, with a mild phenotype, was compound heterozygous for splice site mutation c.3198C/T in exon 46, which creates a cryptic donor site resulting in frame shift and downstream PTC, and mutation c.2972delT in exon 45, which also leads to a downstream PTC.

DISCUSSION

The current canonical features of patients with JEB due to *COL17A1* mutations are skin fragility with generalized sero-hemorrhagic blisters, mucosal involvement, pigmentary changes, atrophic scars, universal alopecia, dystrophic nails and dental abnormalities [13, 14], which are also observed in most of our patients.

Our study provides interesting new clinical information. First, CCA seems to frequently occur in JEB associated with genetic mutations in *COL17A1*, because it affects more than 50% of our patients, with a peculiar involvement of the four limbs. On upper limbs the back of both hands were involved, reminiscent of the pattern of congenital suction blisters, but with deeper ulceration. Lower limb CCA was classical but without orthopedic sequelae as described for DEB patients. Interestingly, the presence of CCA was associated with the most severe phenotypes and skin fragility. Clinically CCA associated with mutation in *COL17A1* presented differently from the extensive CCA described in patients with JEB with pyloric atresia due to anomalies in plectin or integrin $\alpha 6\beta 4$ [2, 15, 16], however no clear correlation with the genotype could be established.

Following the patients' clinical evolution with aging, in a majority of cases a progressive improvement of the skin involvement took place, which was not observed in mucosal involvements that constantly persisted. Accordingly, in adulthood, complications were frequently reported by patients (n=11), which included: mucosal complications (mainly oral and uro-genital involvement, and, at a lower level, also eyes and nose) and dystrophic nails. Universal alopecia and dental abnormalities were found in only half of patients, with no clear correlation between these two manifestations. The young age of our patients can explain such a low percentage, but in a recent article, Kiritsi et al [17] found similar results. Interestingly, Olague-Marchan et al [10] hypothesized that glycine substitutions in the *COL17A1* gene appear to give rise to a novel form of random pitting of dental enamel and hypoplasia. Half of the patients had acceptable social integration and personal development, according to the old denomination of the disease: generalized atrophic benign epidermolysis bullosa (GABEB).

Also, the wide range of phenotype severity in this disease is noticeable. In contrast to patients with favorable evolution of the condition, very severe forms affected three patients, who died in their first months of life: because of sepsis in two instances and renal failure in one case. Sepsis is the most frequent cause of death in patients with severe JEB [15, 18]. Patient 5 with renal failure presented a novel *COL17A1* mutation, c.56delT, which causes a frameshift of the *COL17A1* coding reading frame. Renal disease in generalized intermediate JEB has not been reported yet [2, 18 and 19]. On the contrary, 4 patients with severe neonatal presentation underwent favorable clinical evolution in adulthood. Seven other suffered from systemic complications with malnutrition, musculoskeletal limitations and poor social integration. No cancer or esophageal stricture was reported, as described in literature [16, 18, 19 and 20].

So far, less than 100 patients with genetic mutations in COLXVII have been described [12, 17, 21 and 22]. Confrontation of our results with the previously reported cases confirms the heterogeneity within the constellation of the known *COL17A1* mutations, in which recurrent mutations are rare and hot spot mutations are absent. This feature is contrast with what observed with other genes involved in inherited EB, such as *COL7A1* or *LAMB3*, which can also explain the rarity of this form of the condition. According with other authors, we found that nonsense mutations, insertions and deletions are the most frequent genetic alterations and that missense mutation more commonly localize in col15, the largest collagenic domain of the protein [13, 23, 24 and 25]. Kiritsi et al [17] suggested that most mutations occur in *COL17A1* exon 51 and 52, but our results fail to corroborate this hypothesis. We however confirm that p.Arg1226X is a recurrent European mutation [17]. The recurrent “Italian” p.Arg795X mutation was detected in a French composite heterozygous patient, but not in the four Italian patients of our cohort [17, 22]; neither did we found the recurrent p.Gly803X mutation reported by Kiritsi et al [17]. Mutation p.Arg1303Glu, appears to be recurrent, because it has been published by several teams and seems to be specific of the late-onset or localized JEB phenotype [12, 17 and 21].

Further genotype-phenotype correlations are difficult to establish, but a few considerations can be made in the light of our observations. Presence of a residual

immunofluorescence staining in is the skin biopsy is always associated with a mild phenotype [17]. Missense mutations, in particular those affecting the collagenic domain coll15, and splice site mutations seem to result in milder JEB phenotypes. We were unable to evaluate the possible presence of a dominant effect of missense mutations on the dental enamel in the patients' parents [10]. Similarly, in the case of mutation c.3198C/T mutation in exon 46, which is very similar to the recently published mutation c.3156C/T, we could not explore the patient's parents for possible epithelial recurrent erosion dystrophy [9]. In patients with a nonsense mutations or insertion/deletion mutations leading to PTC, the phenotype is usually severe; in this study, however, a few patients homozygous for a nonsense mutation displayed a mild clinical phenotype. Lack of biological material prevented us to verify whether such a mild phenotype could be explained by expression of a (partially) functional collagen XVII molecule consequent to alternative splicing mechanisms rescuing messenger RNA expression or by spontaneous revertant mosaicism, as reported in the literature [17, 18, 19 and 26]. On the contrary, distal *COL17A1* mutations lead to severe phenotype, which is presumably consequent to premature degradation of mutated messenger RNA and absence of protein expression in the skin, as shown for the recurrent mutation p.Arg1226X [17, 27 and 28].

In conclusion, this study underlines the high variability of phenotypic presentation of inherited JEB associated with genetic mutations in *COL17A1* that range from late JEB onset to severe clinical phenotypes resulting in premature demise of the patients. High frequency of CCA affecting the four limbs in severely affected patients is also reported, as well as a favorable evolution in a majority of patients of the skin involvements over time. We confirm that residual staining of collagen XVII in indirect immunofluorescence of skin biopsy is hallmark of a favorable prognosis. At the moment, however, and with the exception of extremely rare recurrent mutations, valid genotype-phenotype correlations cannot be established. Such correlations will require identification of additional cases of JEB and needs mRNA expression analysis and/or functional studies on collagen XVII.

REFERENCES

- 1- Boeira VL, Souza ES, Rocha B de O et al. Inherited epidermolysis bullosa: clinical and therapeutic aspects. *An Bras Dermatol* 2013; 88(2):185-98.
- 2- Fine JD, Bruckner-Tuderman L, Eady RAJ et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. *J Am Acad Dermatol* 2014; 70(6):1103-26.
- 3- Marinkovich MP, Herron GS, Khavari PA et al. Hereditary Epidermolysis Bullosa. Textbook 5th edition 1999; 1:690-98.
- 4- Franzke CW, Tasanen K, Schumann H et al. Collagenous transmembrane proteins: collagen XVII as a prototype. *Matrix Biology* 2003; 22:299-309.
- 5- Giudice GJ, Emery DJ, and Diaz LA. Cloning and Primary Structural Analysis of the Bullous Pemphigoid Autoantigen BP180. *J Invest Dermatol* 1999; 99:243-50.
- 6- Hopkinson SB, Baker SE, Jones JCR et al. Molecular Genetic Studies of a Human Epidermal Autoantigen (the 180-kD Bullous Pemphigoid Antigen/BP180): Identification of Functionally Important Sequences within the BP180 Molecule and Evidence for an Interaction between BP180 and $\alpha 6$ integrin. *J Cell Biology* 1995; 130(1):117-125.
- 7- Koster J, Geerts D, Favre B et al. Analysis of the interactions between BP180, BP230, plectin and the integrin $\alpha 6\beta 4$ important for hemidesmosome assembly. *J Cell Science* 2002; 116:387-399.
- 8- Tasanen K, Tunggal L, Chometon G et al. Keratinocytes from Patients Lacking Collagen XVII Display a Migratory Phenotype. *Am J Pathol* 2004; 164:2027-2038.
- 9- Frida Jonsson F, Bystrom B, Davidson AE et al. Mutations in Collagen, Type XVII, Alpha 1 (COL17A1) Cause Epithelial Recurrent Erosion Dystrophy (ERED). *Hum Mutat* 2015; 36:463-473.
- 10- Olague-Marchan M, Twining SS, Hacker MK, et al. A disease-associated glycine substitution in BP180 (type XVII collagen) leads to a local destabilization of the major collagen triple helix. *Matrix Biol* 2000; 19:223-33.
- 11- Charlesworth A, Gagnoux-Palacios L, Bonduelle M et al. Identification of a Lethal Form of Epidermolysis Bullosa Simplex associated with a Homozygous Genetic Mutation in Plectin. *J Invest Dermatol* 2003;121:1344-48.
- 12- Vanotti S, Chiaverini C, Charlesworth A et al. Late-onset skin fragility in childhood: a case of junctional epidermolysis bullosa of late onset caused by a missense mutation in *COL17A1*. *B J Dermatol* 2013; 169:714-15.
- 13- Has C, Kern JS. Collagen XVII. *Dermatol Clin* 2010; 28:61-66.
- 14- Yancey KB, Hintner H. Non-Herlitz Junctional Epidermolysis Bullosa. *Dermatol Clin* 2010; 28:67-77.

- 15-Hon KL, Li JJ, Cheng BL, Luk DC et al. Age and etiology of childhood epidermolysis bullosa mortality. *J Dermatol Treat* 2015; 26(2):178-82.
- 16-Dang N, Klingberg S, Rubin AI et al. Differential expression of pyloric atresia in junctional epidermolysis bullosa with ITGB4 mutations suggests that pyloric atresia is due to factors other than the mutations and not predictive of a poor outcome: three novel mutations and a review of the literature. *Acta Derm Venereol* 2008; 88:438-48.
- 17-Kiritsi D, Kern JS, Schumann H et al. Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa. *J Med Genet* 2011; 48:450-7.
- 18-Fine JD, Johnson LB, Weiner M et al. Cause-specific risks of childhood death in inherited epidermolysis bullosa. *J Pediatr* 2008; 152:276-80.
- 19-Fine JD, Mellerio JE. Extracutaneous complications and manifestations in inherited epidermolysis bullosa, part I. *J Am Acad Dermatol* 2009; 61:367-84.
- 20-Fine JD, Mellerio JE. Extracutaneous complications and manifestations in inherited epidermolysis bullosa, part II. *J Am Acad Dermatol* 2009; 61:387-402.
- 21-Yuen WY, Pas HH, Sinke RJ, Jonkman MF. Junctional epidermolysis bullosa of late onset explained by mutations in COL17A1. *Br J Dermatol* 2011; 164:1280-4.
- 22-Pasmooij AMG, Pas HH, Jansen GHL. Localized and generalized forms of blistering in junctional epidermolysis bullosa due to COL17A1 mutations in the Netherlands. *British J Dermatol* 2007;156:861-870.
- 23-Huilaja L, Hurskainen T, Autio-Hartmainen H et al. Glycine substitution mutations cause intracellular accumulation of collagen XVII and affect its post-translational modifications. *J Invest Dermatol* 2009;129:2309-6.
- 24-Vaisanen L, Has C, Franzke C, et al. Molecular mechanisms of junctional epidermolysis bullosa: Col15 domain mutations decrease the thermal stability of collagen XVII. *J Invest Dermatol* 2005;125:1112-18.
- 25-Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. *J Invest Dermatol* 1992; 99:243-50.
- 26-Ruzzi L, Pas H, Posteraro P, Mazzanti C et al. A homozygous nonsense mutation in type XVII collagen gene (COL17A1) uncovers an alternatively spliced mRNA accounting for an unusually mild form of non-Herlitz junctional epidermolysis bullosa. *J Invest Dermatol* 2001; 116:182-7.
- 27-Huber, M., Floeth, M., Borradori, L et al. Deletion of the cytoplasmic domain of BP180/collagen XVII causes a phenotype with predominant features of epidermolysis bullosa simplex. *J. Invest. Dermatol* 2002; 118:185-192.
- 28-Tasanem K, Tunggal L, Chometon G et al. Keratinocytes from patients lacking collagen XVII display a migratory phenotype. *Am J Pathol* 2004;164:2027-38.

Figure 1. Phenotypic variability in junctional epidermolysis bullosa (JEB) patients with COL17A1 mutations. (a) dystrophic nails. (b) dental abnormalities localized in four limbs. (d) blister in an upper limb.



Figure 2. Distribution of collagen XVII mutations in this study. Schematic representation of the protein with corresponding domains and binding site proteins. The mutations underlined are novel, asterix corresponds to homozygous mutations and recurrent mutations are grayed. Nonsense and missense mutations are described on protein level, whereas frameshift, splice site, deletion and insertion mutations are described on cDNA level.




Table 1. Summary of clinical, immunohistological and molecular data of patients. X: Premature terminal codon. SS: Splice site mutation. A: Alanine. E: Acide glutamique. G: Glycine. Y: Tyrosine. L: Leucine. Q: Glutamine. R: Arginine. S: Serine. NA: Non Available. PMD: Psycho motor delay. Ins : Insertion. Del: Deletion. Mut : Mutation. Prot: Protein. Pb: Problems.

Patients	Age	mut cDNA 1	mut prot 1	exon 1	mut cDNA 2	mut prot 2	exon 2	IF	ACC	Alopecia	Mucosa lesions	Nails pb	Dental pb	Evolution	
								n=29	n=25	n=25	n=25	n=25	n=25	n=25	
1	23	c.3908G>A	p.R1303Q	52	c.3908G>A	p.R1303Q	52	-	no	no	oral	yes	no	good	
2	71	c.1852 G/A	p.G618S	23	c.1852 G/A	p.G618S	23	±	no	yes	urogenital	no	no	good	
3	17	c.2383C/T	p.R795X	33	c.1239_1340delGT	p.V413fs	16	-	no	no	oral/uro-genital	yes	yes	good	
JEB generalized															
4	NA	c.1873C/T	p.R625X	23	c.1873C/T	p.R625X	23	-	4 limbs	yes	oral/uro-genital	yes	no	demise at 1month/meningitis	
5	NA	c.56delT	p.V19fs	3	c.56delT	p.V19fs	3	-	4 limbs	yes	oral/uro-genital	yes	no	demise at 1month/renal failure	
6	NA	c.2062delC	p.R688fs	26	c.3676C/T	p.R1226X	51	-	4 limbs	yes	oral/uro-genital/orl	yes	no	demise at 3month/sepsis	
7	3	c.412C/T	p.R138X	7	c.412C/T	p.R138X	7	-	no	yes	oral/orl/eyes	yes	yes	malnutrition/PMD/retraction	
8	2	c.3505C/T	p.R1169X	49	c.2544delA	p.G848fs	36	-	4 limbs	yes	oral/urogenital	yes	yes	PMD	
9	2	ongoing			ongoing			-	lower limbs	yes	oral/orl/eyes	yes	no	malnutrition/PMD/retraction	
10	30	c.2585_2586del2	p.P862R	37	c.2585_2586del2	p.P862R	37	-	lower limbs	yes	oral/uro-genital/eyes	yes	yes	malnutrition/retraction	
11	54	c.621 C/G	p.Y207X	10	c.621 C/G	p.Y207X	10	-	no	yes	oral/urogenital/orl	yes	yes	depression	
12	22	c.380-1G>A	SS	7	c.1696C/T	p.R566X	19	-	lower limbs	yes	oral/urogenital/eyes	yes	yes	malnutrition/depression	
13	2	c.3539insC	p.P1180fs	50	c.3539insC	p.P1180fs	50	-	4 limbs	no	oral/uro-genital	yes	no	malnutrition	
14	0	c.3579G/A	p.W1193X	50	c.3786_3789del4	p.F1262fs	52	-	4 limbs	no	oral/nose	yes	no	heavy local care	
15	0	c.621C/G	p.Y207X	10	c.621 C/G	p.Y207X	10	±	upper limbs	no	oral	no	no	heavy local care	
16	17	c.1482_1483ins3	ins 1AA	18	c.1482_1483ins3	ins 1AA	18	±	4 limbs	yes	oral/eyes	yes	no	good	
17	9	c.1373C/A	p.C458X	17	c.1373C/A	p.C458X	17	-	4 limbs	yes	oral	yes	yes	good	
18	13	c.3487G/T	p.E1163X	49	c.3487G/T	p.E1163X	49	-	4 limbs	yes	oral/orl	yes	yes	good	
19	11	c.3827msC	p.P1276fs	52	c.3676C/T	p.R1226X	51	-	4 limbs	yes	oral	yes	yes	good	
20	32	c.1336G/A	p.G446S	17	c.1745-2A>C	SS	21	-	no	yes	oral/urogenital/nose	yes	yes	good	
21	16	c.3175delG	p.E1059fs	46	c.1336G/A	p.G446S	17	-	no	no	oral/urogenital	yes	yes	good	
22	25	c.2551+1G>A	SS	36	c.2551+1G>A	SS	36	-	no	no	oral	yes	yes	good	
23	17	c.2551+1G>A	SS	36	c.2551+1G>A	SS	36	-	no	no	oral	yes	yes	good	
24	13	c.3198C/T	SS	46	c.2972delT	p.V991fs	45	±	no	no	oral	yes	yes	good	
25	74	NF	NF	NF	NF	NF	NF	±	no	no	oral	yes	yes	good	
26	20	c.1141+2T>C	SS	14	c.1141+2T>C	SS	14	-	NA	NA	NA	NA	NA	no info	
27	14	c.1817G>A	p.G606D	22	c.1817G>A	p.G606D	22	-	NA	NA	NA	NA	NA	no info	
28	48	c.2336-2A>G	SS	32	c.2336-2A>G	SS	32	NA	NA	NA	NA	NA	NA	no info	
29	20	c.4207C/T	p.Q1403X	53	c.2336-1G>T	SS	32	-	NA	NA	NA	NA	NA	no info	
30	12	c.3288_3295del8	p.V1095fs	48	c.3288_3295del8	p.V1095fs	48	-	NA	NA	NA	NA	NA	no info	

SERMENT D'HIPPOCRATE

Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité.

Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux.

Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte, je ne ferai pas usage de mes connaissances contre les lois de l'humanité.

J'informerai les patients des décisions envisagées, de leurs raisons et de leurs conséquences. Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences. Je donnerai mes soins à l'indigent et à quiconque me les demandera. Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire.

Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les mœurs.

Je ferai tout pour soulager les souffrances. Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément.

Je préserverai l'indépendance nécessaire à l'accomplissement de ma mission. Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés.

J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité.

Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque.

ABSTRACT

Background: Junctional epidermolysis bullosa (JEB) associated with *COL17A1* genetic mutations is a rare genodermatosis characterized by skin and mucosal fragility due to impaired expression of collagen type XVII, an adhesion protein component of the hemidesmosomes. Clinical phenotypes span from severe forms causing early demise to late onset associated with limited involvement.

Objective: We aimed at defining the genotypes of a large cohort of JEB patients with *COL17A1* mutations.

Methods: Diagnoses were first established by immunofluorescence analyses of skin biopsies followed by genetic screening for *COL17A1* mutations between June 1993 and July 2015.

Results: A wide panel of phenotypes including lethal and mild late-onset forms was observed in the 30-patient cohort. Fourteen of 25 patients also presented with extensive congenital aplasia cutis, while in 13/25 patients involvement improved along with age at the skin but not at the mucosa level. Residual staining of collagen XVII in skin correlated with favorable prognoses. Of the 34 *COL17A1* mutations identified, 24 are novel. Three of them (p.Arg1226X, exon 51; p.Gly446Ser, exon 17; p.Tyr207X exon 10) are recurrent in European patients. If missense and splice site mutations correlated well with mild phenotypes, no other clear phenotype-genotype relationship could be established.

Discussion: We report novel clinical aspects of JEB associated with *COL17A1* genetic mutations. Except for recurrent mutations, a genotype-phenotype correlation is difficult to establish and needs mRNA analysis and/or functional studies.

Key words: Epidermolysis Bullosa ; Collagen XVII ; *COL17A1* ; Cutis Congenital aplasia ; phenotype.

RESUME

Introduction: L'épidermolyse bulleuse héréditaire de type jonctionnelle (JEB) associée à des mutations du gène *COL17A1* est une génodermatose rare caractérisée par une fragilité cutanéomuqueuse due à une altération de l'expression du collagène de type XVII, un composant des protéines d'adhésion des hémidesmosomes. Le phénotype varie de formes graves entraînant une mort prématurée à des formes tardives avec une atteinte cutanéomuqueuse limitée.

Objectif: Nous avons cherché à définir le profil génotypique et phénotypique d'une grande cohorte de patients atteints de JEB et présentant des mutations du gène *COL17A1*.

Méthodes: Le diagnostic a été d'abord établi par analyse des biopsies cutanées par immunofluorescence suivie d'une recherche génétique des mutations du gène *COL17A1*.

Résultats: Une grande variété de phénotypes, allant des formes létales aux formes bénignes, a été observée dans notre cohorte de 30 patients. Quatorze patients sur 25 présentaient une vaste aplasie cutanée congénitale, tandis que 13 patients sur 25 présentaient une atteinte cutanée d'évolution favorable avec l'âge, sans amélioration de l'atteinte muqueuse. La coloration résiduelle du collagène XVII observée lors de l'immunofluorescence indirecte était corrélée à un pronostic favorable. Sur les 34 mutations du gène *COL17A1* identifiées, 24 étaient nouvelles. Trois d'entre elles (p.Arg1226X, exon 51; p.Gly446Ser, exon 17; p.Tyr207X exon 10) étaient récurrentes chez nos patients européens. Si les mutations faux-sens et les mutations au niveau des sites d'épissage sont bien corrélés avec des phénotypes modérés, aucune autre corrélation génotypique-phénotypique n'a pu être clairement établi.

Discussion: Nous rapportons de nouveaux aspects cliniques des JEB associées aux mutations du gène *COL17A1*. À l'heure actuelle et à l'exception des mutations récurrentes extrêmement rares, une corrélation génotypique-phénotypique valide ne peut pas être établie. Ces corrélations nécessitent l'identification de cas supplémentaires de JEB.

Mots clés : Epidermolyse bulleuse ; Collagène XVII ; *COL17A1* ; aplasie cutanée congénitale ; phénotype.